Clinical Trials in North Carolina

Showing 15521-15540 of 17,526 trials

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

NCT00899977

A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP \> 140 mmHg and a DBP \> 90 mmHg) randomized in a double-blind fashion to receive 4 single escalating doses of study medication in clinic.

Refractory Hypertension

Targacept Inc.1 participantsStarted May 2009

Winston-Salem, North Carolina, United States

COMPLETED41 miles

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

NCT00380796

The purpose of this long-term observational study is designed to collect additional information on incidence of cancer and cause of death among patients who have participated in clinical trials of infliximab in the treatment of COPD. Patients must have received at least 1 dose of study agent (ie, placebo or infliximab) in the primary studies to be eligible for participation in this long-term follow-up study. Information on deaths and cancers will be collected twice yearly for a period of 5 years from each patient's last safety visit in the primary study.

COPDPulmonary Disease, Chronic Obstructive

Centocor, Inc.88 participantsStarted Apr 2006

Anaheim, California, United States • San Diego, California, United States • Bay Pines, Florida, United States +23 more locations

TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension

A Long-term Safety Study of Infliximab in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).

Find Trials by Condition in North Carolina

RESTART C0168Z05 Rheumatoid Arthritis Study

Nutrition Intervention in Treating Women With Breast Cancer

Kineflex Artificial Disc System to Treat Degenerative Disc Disease (DDD)

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer

A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

RapidTEG MA Validation

Crosser Enters The Right Arterial Lumen

Intervention to Retain HIV-positive Patients in Medical Care

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Comparison of SureCALL® Labor Monitor® and Tocodynamometer Measurement in Preterm and Term Pregnant Women

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis